Search

Smith & Nephew PLC

Slēgts

1,377.5 -0.07

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1369

Max

1378.5

Galvenie mērījumi

By Trading Economics

Ienākumi

296M

Pārdošana

3B

P/E

Sektora vidējais

32.286

21.981

EPS

0.429

Dividenžu ienesīgums

2.83

Peļņas marža

9.895

Darbinieki

17,000

EBITDA

723M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+4.18% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.83%

4.61%

Nākamais dividenžu datums

2025. g. 7. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.5B

11B

Iepriekšējā atvēršanas cena

1377.57

Iepriekšējā slēgšanas cena

1377.5

Smith & Nephew PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. okt. 20:49 UTC

Peļņas

Correction to Thermo Fisher Article on Oct. 22

2025. g. 23. okt. 23:51 UTC

Tirgus saruna

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025. g. 23. okt. 23:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 23. okt. 23:49 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025. g. 23. okt. 23:37 UTC

Tirgus saruna

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025. g. 23. okt. 22:58 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 23. okt. 22:57 UTC

Tirgus saruna

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025. g. 23. okt. 22:49 UTC

Iegādes, apvienošanās, pārņemšana

How Trump Sparked a New Era of State Capitalism -2-

2025. g. 23. okt. 22:49 UTC

Iegādes, apvienošanās, pārņemšana

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025. g. 23. okt. 22:17 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025. g. 23. okt. 21:41 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025. g. 23. okt. 21:05 UTC

Peļņas

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025. g. 23. okt. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 23. okt. 20:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 23. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 23. okt. 20:35 UTC

Peļņas

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025. g. 23. okt. 20:28 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025. g. 23. okt. 20:15 UTC

Tirgus saruna
Peļņas

Global Commodities Roundup: Market Talk

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q Adj EPS $1.71

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q Sales $5.52B

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q EPS $1.67

2025. g. 23. okt. 20:09 UTC

Peļņas

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025. g. 23. okt. 20:07 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 23. okt. 20:07 UTC

Tirgus saruna
Peļņas

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025. g. 23. okt. 20:07 UTC

Peļņas

Blackstone Looks to IPOs for Investment Exits -- Update

2025. g. 23. okt. 20:05 UTC

Peļņas

Intel 3Q Gross Margin 38.2% >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel: 4Q Guidance Excludes Altera >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel Sees 4Q Adj EPS 8c >INTC

Smith & Nephew PLC Prognoze

Cenas mērķis

By TipRanks

4.18% augšup

Prognoze 12 mēnešiem

Vidējais 1,453.85 GBX  4.18%

Augstākais 1,700 GBX

Zemākais 1,250 GBX

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

7

Pirkt

6

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat